22 vials of compounded tirzepatide recalled in the US over lack of sterility assurance
- Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one vial of NAD+ injection because their sterility cannot be assured.
- The FDA classified the compounded tirzepatide recall as Class II on 8 October 2026.
- Brand-name Mounjaro and Zepbound are not part of the recall.
- The FDA reported no injuries linked to the recalled tirzepatide vials.
According to a US Food and Drug Administration enforcement report, North Carolina-based Apothecary Pharma is voluntarily recalling 22 vials of compounded tirzepatide and one vial of NAD+ injection nationwide because of a lack of assurance of sterility. The FDA classified the recall as Class II on 8 October 2026, and it was widely reported on 21 October.
What is recalled
The product is tirzepatide injection 18 mg/mL in a 4 mL multi-dose vial (NDC 85091-001-18), lots AP-202622 to AP-202625 and AP-202627 to AP-202644, with beyond-use dates from early October to late November 2026. Eli Lilly's brand-name Mounjaro and Zepbound are not affected.
Also read: MHRA seizes £2 million of fake retatrutide and tirzepatide weight-loss pens in Birmingham
What it means
Class II means use of the product may cause temporary or medically reversible health problems, and serious harm is unlikely. A lack of sterility assurance does not by itself mean contamination was found, only that the firm cannot confirm sterile production. No injuries have been reported. The FDA sent the company a warning letter in December 2025 over sterile manufacturing deficiencies but has not linked it to this recall.
Advice for patients
People using compounded tirzepatide should check the lot number, stop using recalled product and contact their pharmacist or prescriber. Anyone with fever, redness, swelling or worsening pain after an injection should seek care. Compounded drugs are not reviewed by the FDA before they are sold.
Sources: Managed Healthcare Executive, FOX 5 New York
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
Why was Apothecary Pharma's compounded tirzepatide recalled?
Apothecary Pharma recalled 22 vials of compounded tirzepatide because the company cannot assure they are sterile, according to an FDA enforcement report.
Does the tirzepatide recall include Mounjaro or Zepbound?
No. The tirzepatide recall covers only Apothecary Pharma's compounded product, not Eli Lilly's brand-name Mounjaro or Zepbound.
Which tirzepatide lots are recalled?
The recalled tirzepatide lots are AP-202622 to AP-202625 and AP-202627 to AP-202644, 18 mg/mL in 4 mL vials.
What does Class II mean for the compounded tirzepatide recall?
Class II means the recalled compounded tirzepatide may cause temporary or medically reversible health problems, and serious harm is unlikely.
What should people who used recalled compounded tirzepatide do?
People who used recalled compounded tirzepatide should stop it, contact their pharmacist or prescriber, and seek care for fever, redness or swelling at the injection site.



